42.40
1.78 (4.38%)
| Previous Close | 40.62 |
| Open | 40.86 |
| Volume | 1,256,029 |
| Avg. Volume (3M) | 906,757 |
| Market Cap | 2,470,508,288 |
| Price / Earnings (Forward) | 222.22 |
| Price / Sales | 4.97 |
| Price / Book | 6.63 |
| 52 Weeks Range | |
| Earnings Date | 28 Oct 2024 |
| Profit Margin | -13.68% |
| Operating Margin (TTM) | -4.34% |
| Diluted EPS (TTM) | -1.35 |
| Quarterly Revenue Growth (YOY) | 21.40% |
| Total Debt/Equity (MRQ) | 7.53% |
| Current Ratio (MRQ) | 1.77 |
| Operating Cash Flow (TTM) | 14.18 M |
| Levered Free Cash Flow (TTM) | 86.61 M |
| Return on Assets (TTM) | -3.21% |
| Return on Equity (TTM) | -17.72% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | Inari Medical, Inc. | Bullish | Bearish |
Stockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Average | 0.38 |
|
Inari Medical Inc is a medical device company focused on developing products to treat patients suffering from Chronic Venous Disease. Its product portfolio includes; ClotTriever, for the removal of the clot from peripheral blood vessels and treats patients suffering from deep vein thrombosis. The FlowTriever System product is used for the treatment of pulmonary embolism, InThrill system to treat small vessel thrombosis, LimFlow system and others. Geographically, the company generates majority of its revenue from United States and rest from International markets. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Growth |
| % Held by Insiders | 8.75% |
| % Held by Institutions | 96.11% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 74.00 (Canaccord Genuity, 74.53%) | Buy |
| Median | 51.00 (20.28%) | |
| Low | 47.00 (Leerink Partners, 10.85%) | Hold |
| Average | 56.67 (33.66%) | |
| Total | 2 Buy, 4 Hold | |
| Avg. Price @ Call | 47.43 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Baird | 29 Oct 2024 | 67.00 (58.02%) | Buy | 49.18 |
| Canaccord Genuity | 29 Oct 2024 | 74.00 (74.53%) | Buy | 49.18 |
| Piper Sandler | 29 Oct 2024 | 52.00 (22.64%) | Hold | 49.18 |
| 26 Aug 2024 | 50.00 (17.92%) | Hold | 43.04 | |
| Truist Securities | 29 Oct 2024 | 50.00 (17.92%) | Hold | 49.18 |
| 14 Oct 2024 | 46.00 (8.49%) | Hold | 42.20 | |
| Stifel | 17 Sep 2024 | 50.00 (17.92%) | Hold | 44.10 |
| Leerink Partners | 03 Sep 2024 | 47.00 (10.85%) | Hold | 43.74 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 06 Nov 2024 | Announcement | Inari Medical to Participate in the Jefferies London Healthcare Conference |
| 29 Oct 2024 | Announcement | PEERLESS Results Show Superiority of FlowTriever® Compared to Catheter-Directed Thrombolytics for Intermediate-Risk Pulmonary Embolism |
| 28 Oct 2024 | Announcement | Inari Medical Reports Third Quarter 2024 Financial Results |
| 21 Oct 2024 | Announcement | Okami Medical Announces Closing Of $32.5M Financing |
| 15 Oct 2024 | Announcement | Inari Medical Announces Partnership with AVF and NBCA on DEFIANCE Trial |
| 07 Oct 2024 | Announcement | Inari Medical to Host Analyst and Investor Meeting Following PEERLESS RCT Presentation |
| 07 Oct 2024 | Announcement | Inari Medical to Announce Third Quarter 2024 Financial Results |
| 29 Aug 2024 | Announcement | Inari Medical Announces PEERLESS Data to be Presented During the Late-Breaking Clinical Trial Sessions at TCT 2024 |
| 21 Aug 2024 | Announcement | Inari Medical to Present at Upcoming Investor Conferences |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |